MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

(TSV:NGEN)

5.000 -0.260 (-4.94%)
Streaming Delayed Price Updated: 3:59 PM EDT, Mar 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 114,157
Open 5.200
Bid (Size) 4.950 (20)
Ask (Size) 5.000 (2)
Prev. Close 5.260
Today's Range 4.870 - 5.300
52wk Range 2.570 - 8.490
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
From NervGen Pharma Corp.
Via GlobeNewswire

Performance

YTD
-36.9%
-36.9%
1 Month
-12.9%
-12.9%
3 Month
-13.8%
-13.8%
6 Month
+30.5%
+30.5%
1 Year
+81.8%
+81.8%

More News

Read More
News headline image
NervGen Pharma to Participate at Upcoming Investor Conferences
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Begins Trading on Nasdaq Today
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
From NervGen Pharma Corp.
Via GlobeNewswire
News headline image
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Sciences Investor Forum Agenda Announced for March 13th
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
Life Science Investor Forum Agenda Announced for June 22nd
From Virtual Investor Conferences
Via GlobeNewswire
News headline image
NervGen Pharma Announces Leadership Transition
Via Newsfile
News headline image
Encode Ideas, L.P. Announces the Initiation of Research Coverage on NervGen Pharma Corp.
Via Newsfile
News headline image
NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University
From NervGen Pharma Corp.
Via Business Wire
News headline image
NervGen Engages Vorticom Inc. to Provide Media Relations Services
Via Newsfile
News headline image
NervGen Pharma Enters into Research Agreement with Sylics to Study NVG-291 in Alzheimer's Disease Models
Via Newsfile
News headline image
NervGen Pharma Reports First Quarter 2021 Results
Via Newsfile
News headline image
NervGen Pharma Announces Closing of Overnight Marketed Equity Offering
Via Newsfile
News headline image
NervGen Pharma Grants Stock Options
Via Newsfile
News headline image
NervGen Pharma Announces First Subject Dosed in Phase 1 Clinical Trial of NVG-291
Via Newsfile
News headline image
NervGen Pharma Corp. Announces Overnight Marketed Equity Offering
Via Newsfile
News headline image
NervGen Pharma Grants Stock Options
Via Newsfile
News headline image
NervGen Pharma Announces Appointment of Pharma Veteran Dr. Daniel Mikol as Chief Medical Officer
Via Newsfile

Frequently Asked Questions

Is NGEN publicly traded?
Yes, NGEN is publicly traded.
What exchange does NGEN trade on?
NGEN trades on the Toronto Venture Stock Exchange
What is the ticker symbol for NGEN?
The ticker symbol for NGEN is NGEN on the Toronto Venture Stock Exchange
What is the current price of NGEN?
The current price of NGEN is 5.000
When was NGEN last traded?
The last trade of NGEN was at 03/13/26 03:59 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story